secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001411685-25-000046
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials
--------------------------------------------------------------------------------

- FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.
- Cash, cash equivalents and marketable securities $80.5M as of March 31, 2025.
- PALISADE-3 fasedienol topline results expected Q4 2025; PALISADE-4 results expected H1 2026.
- Filed prospectus supplement to sell up to $175M common stock via ATM (replacing $100M prior); ~$3.4M already sold.
- Itruvone for MDD planning further Phase 2; PH80 for menopausal hot flashes preparing U.S. IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/0001411685-25-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/vtgn-20250617.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer